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Abstract
BACKGROUND—Blood molecular profiling of circulating tumor cells (CTCs) can enable 
monitoring of patients with metastatic melanoma during checkpoint inhibitor immunotherapy 
(CII) and in combination with targeted therapies. We developed a microfluidics-based CTC 
platform to explore CTC profiling utility in CII-treated patients with melanoma using a melanoma 
messenger RNA (mRNA)/DNA biomarker panel.
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METHODS—Blood samples (n = 213) were collected prospectively from 75 American Joint 
Committee on Cancer-staged III/IV melanoma patients during CII treatment and those enriched 
for CTCs. CTC profiling was performed using 5 known melanoma mRNA biomarkers and BRAF 
V600E DNA mutation. CTC biomarker status associations with clinical outcomes were assessed.
RESULTS—CTCs were detected in 88% of blood samples from patients with melanoma. CTC-
derived biomarkers and clinical variables analyzed using classification and regression tree analysis 
revealed that a combination of lactate dehydrogenase, CTC-mRNA biomarkers, and tumor BRAF–
mutation status was indicative of clinical outcomes for patients with stage IV melanoma (n = 52). 
The panel stratified low-risk and high-risk patients, whereby the latter had poor disease-free (P = 
0.03) and overall survival (P = 0.02). Incorporation of a DNA biomarker with mRNA profiling 
increased overall CTC-detection capability by 57% compared to mRNA profiling only. RNA 
sequencing of isolated CTCs identified significant catenin beta 1 (CTNNB1) overexpression (P 
<0.01) compared to nondisease donor blood. CTC-CTNNB1 was associated with progressive 
disease/stable disease compared to complete-responder patient status (P = 0.02). Serial CTC 
profiling identified subclinical disease in patients who developed progressive disease during 
treatment/follow-up.
CONCLUSIONS—CTC-derived mRNA/DNA biomarkers have utility for monitoring CII, 
targeted, and combinatorial therapies in metastatic melanoma patients.
Patients with metastatic melanoma have access to targeted therapies and checkpoint inhibitor 
immunotherapy (CII)6 for disease management. However, robust biomarkers are lacking for 
patient stratification and assessment of CII efficacy alone or in combination with targeted 
therapies (1). Serial tumor biopsies to monitor evolving tumor profiles and treatment 
efficacy are not feasible. Circulating tumor cells (CTCs), indicative of subclinical disease, 
may enable minimally invasive monitoring of patients with metastatic melanoma (2, 3). 
Previous multicenter phase II/III studies (4–8) demonstrated the prognostic utility of a 
defined CTC-derived messenger RNA (mRNA) biomarker panel (9) during follow-up and 
disease outcome. However, the utility of CTCs for CII and combinatorial therapies is not 
fully established as emerging CTC-derived, CII-related melanoma biomarkers have yet to be 
validated in clinical trials.
Difficulties in identifying robust CII-related CTC biomarkers in blood are attributed to low 
CTC abundance and the heterogeneous metastatic melanoma landscape. To address 
melanoma heterogeneity (10, 11) and to improve monitoring of disease status during 
therapy, we developed a CTC molecular profiling assay following nonepithelial cellular 
adhesion molecule-based CTC enrichment (12) utilizing a panel of known mRNA and DNA 
melanoma blood biomarkers. This CTC-derived biomarker panel was applied to 
prospectively collected blood samples from metastatic melanoma patients actively receiving 
CII, combinatorial modern therapies, or during follow-up of therapy to explore the potential 
6Nonstandard abbreviations: CII, checkpoint inhibitor immunotherapy; CTC, circulating tumor cell; mRNA, messenger RNA; SJHC, 
Providence Saint John’s Health Center; AJCC, American Joint Committee on Cancer; PD, progressive disease; SD, stable disease; 
qRTPCR, quantitative reverse transcriptase-PCR; WGA, whole-genome amplification; CTC-DNA, CTC-derived DNA; WT, BRAF 
wild-type; RNA-seq, RNA sequencing; OS, overall survival; DFS, disease-free survival; LDH, lactate dehydrogenase; URL, upper 
reference limit; CART, classification and regression tree; CTC-BRAF, CTC-derived BRAF V600E mutation; BRAF-V600E mutation, 
BRAF mutation; HR, hazard ratio.
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of CTC profiling for assessing CII therapeutic efficacy. Here we describe the potential utility 
for CTC-mRNA/ DNA multimarker monitoring in patients with melanoma receiving CII.
Materials and Methods
PATIENT SAMPLES AND CELL LINES
All tissue and blood samples were obtained from consented patients with melanoma treated 
at Providence Saint John’s Health Center (SJHC) between 2015 and 2017 in accordance 
with the Western Institutional Review Board (MORD-RTPCR-0995). Current American 
Joint Committee on Cancer (AJCC; 8th ed) staging guidelines were applied. Prospective 
blood samples (n = 213) from 75 patients with melanoma were included (Table 1). Fifty 
patients provided 2 to 9 serial samples per patient. Patients and respective therapies are 
shown in Table 1 in the Data Supplement that accompanies the online version of this article 
at http://www.clinchem.org/content/vol66/issue1. Treatment response was assessed by 
computerized tomography/magnetic resonance imaging every 3 months, determined by a 
single physician (S.J. O’Day) according to Response Evaluation Criteria In Solid Tumors 
1.1 criteria denoting progressive disease (PD), stable disease (SD), partial response, 
complete response, or no evidence of disease.
Established metastatic melanoma cell lines (EB, M14, and HM-0525) with known 
mRNA/DNA biomarker status (13) from melanoma patients who received surgery at John 
Wayne Cancer Institute were used as controls in quantitative reverse transcriptase-PCR 
(qRT-PCR) assays and CTC spike-in experiments.
CTC ENRICHMENT
Blood was collected in Cell-Free DNA BCT® tubes (Streck) and processed within 48 h (6). 
Ten milliliters of blood was prepared for the FX1 system (14) for automated label-free CTC 
enrichment as previously described (15). EpiCentre MasterPure™ Complete DNA and RNA 
purification kit was used to extract nucleic acids from enriched CTCs according to the 
manufacturers’ protocols with 2 modifications comprising an overnight incubation at ‒80°C 
after addition of lysis buffer and addition of 1 μL Pellet Paint® NF Co-Precipitant (Millipore 
Sigma) during nucleic acid precipitation.
qRT-PCR ASSAYS
Nucleic acids extracted from enriched-CTC samples were evaluated in a qRT-PCR assay 
containing 5 biomarkers (CTC-mRNA panel), MAGE family member A3 (MAGEA3)7, 
melan-A (MLANA), beta-1,4-N-acetylgalactosaminyltransferase 1 (B4GALNT1), PAX3 
paired box 3 (PAX3), and tRNA-Pro (anticodon AGG) 2–6 (DCT), previously established in 
multiple phase II/III melanoma clinical trials (4–8). Assays were performed (6, 7, 9, 16) in 
accordance with Reporting Recommendations for Tumor Marker Prognostic Studies criteria.
7Human genes: MAGEA3, MAGE family member A3; MLANA, melan-A; B4GALNT1, beta1,4-N-acetyl-galactosaminyltransferase 
1; PAX3, paired box 3; TRP-AGG2-6, tRNA-Pro (anticodon AGG) 2-6; CTNNB1, catenin beta 1; B2M, beta-2-microglobulin; 
SDHA, succinate dehydrogenase complex flavoprotein subunit A.
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The novel CTC-mRNA catenin beta 1 (CTNNB1) biomarker was evaluated with the 
Integrated DNA Technologies’ predesigned CTNNB1 qRT-PCR assay and was performed 
according to the manufacturer’s specifications. The qRT-PCR assay with a positive 32–cycle 
cutoff was established based on assessment of 10 healthy donor leukocytes post-FX1 
enrichment in triplicate. The assay was performed with positive (LF0023, M14, and EB cell 
lines), negative (mouse line NIH3T3), and no template controls and beta-2-microglobulin 
(B2M) (17) and succinate dehydrogenase complex flavoprotein subunit A (SDHA) (18) 
housekeeping genes for internal control and RNA integrity verification. Samples that 
amplified before the 32-cycle cutoff were considered positive for CTNNB1.
BRAF V600E MUTATION DIGITAL DROPLET PCR ASSAY
Nucleic acids extracted from enriched-CTCs underwent whole-genome amplification 
(WGA) using the True-Prime™ WGA kit (Expedeon) followed by purification using 
Genomic DNA Clean & Concentrator™ (ZYMO Research Corp) according to the 
manufacturers’ specifications. WGA of melanoma CTC-derived DNA (CTC-DNA) isolated 
in vitro and from patients with melanoma were subjected to the RainDrop Digital Droplet 
PCR BRAF V600E Assay (RainDance™ Technologies) and performed according to the 
manufacturer’s protocol. The assay contained at least a 0.01% mutant sensitivity when a 
reconstituted BRAF V600E DNA mutant standard of 0.01% was assessed (see Fig. 1 in the 
online Data Supplement) and a limit of blank cutoff of ≥2 mutant-positive droplets was 
applied. The assay’s limit of blank was established from healthy donor leukocytes (n = 10) 
and CTCs (n = 25) from tumor BRAF wild-type (WT) patients in accordance with the 
manufacturer’s protocol. All CTC WT control samples were negative for BRAF V600E 
mutation detection postenrichment. Samples with insufficient CTC-DNA or unknown tumor 
BRAF V600E mutation status at the time of blood collection were excluded from digital 
droplet PCR analysis.
IMMUNOFLUORESCENCE STAINING
CTCs isolated from melanoma patients were identified by immunofluorescence staining for 
MLANA, a known melanoma-associated antigen (7), using an Alexa Fluor 488® conjugated 
(1:50; Santa Cruz Biotechnology) antibody. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (Thermo Fisher Scientific). Images were obtained using a Nikon 
Eclipse Ti microscope as previously described (18).
RNA IN SITU HYBRIDIZATION
CTC-matched formalin-fixed, paraffin-embedded tumor tissues were evaluated by RNA in 
situ hybridization for CTNNB1 expression (Hs-CNNTB1 probe #311731) using the 
RNAscope Multiplex Fluorescent Kit V2 (Advanced Cell Diagnostics) according to the 
manufacturer’s instructions. Immunofluorescence staining was observed under the 
fluorescence microscope (Nikon) and representative images were taken for each condition. 
Assays for formalin-fixed, paraffin-embedded tissues were developed and optimized as 
previously described (19). Images were analyzed based on ACD guidelines for in situ 
hybridization scoring. 3-plex negative (#320871) and positive (#320861) probes served as 
controls and target bacterial dihydrodipicolinate reductase gene and housekeeping genes, 
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respectively. In situ hybridization staining images for specific genes were assessed only 
when proper positive and negative controls were identified.
CTC RNA SEQUENCING
Post-CTC enrichment, RNA extracted from 3 patients’ CTCs underwent RNA sequencing 
(RNA-seq) at the John Wayne Cancer Institute Sequencing Center (20). CTC RNA-seq next-
generation sequencing reads were mapped to the GENCODE v19 human genome reference 
using STAR v2.4.2a with default parameters and read counts generated using the “–
quantMode GeneCounts” function. CTC results were normalized and compared to 6 healthy 
donors blood leukocytes RNA-seq data (Gene Expression Omnibus project numbers 
GSE53655; SRR1060788, SRR1060789, SRR1060790, SRR1060791, SRR1060792, 
SRR1060793) (21). Expression of CTNNB1 in nondiseased tissues was explored using the 
Genotype-Tissue Expression Portal (22). Significantly differentially expressed genes were 
identified using the DESeq2 bioconductor package with a model controlling for sample sex. 
RNA-seq data and read counts from single sequencing runs were deposited in the National 
Center for Biotechnology Information Gene Expression Omnibus database (GSE100565).
BIOSTATISTICAL ANALYSIS
Fisher exact test was performed for categorical variables. Overall survival (OS) was 
calculated from time of first sample analysis until death or last contact. Disease-free survival 
(DFS) was the time to melanoma disease recurrence or death. Lactate dehydrogenase (LDH; 
U/L) using a cutoff of ≤1.5 × (low LDH) or >1.5 × (high LDH), the upper reference limit 
(URL) (23, 24), were compared for clinical outcomes. CTC-derived molecular biomarkers 
and clinical variables were evaluated at the collection time in all 75 patients. CTC-mRNA 
was defined as low CTC-mRNA (n <2) or high CTC-mRNA (n [mtqu]2) as previously 
reported (7); CTC-CTNNB1 mRNA and CTC BRAF V600E mutation were defined as 
negative or positive as described above.
To evaluate the association of CTC-derived molecular biomarkers and clinical variables with 
OS and DFS, we performed classification and regression tree (CART) analysis (25) using 
statistical R package “rpart” (26). CART builds a decision tree that hierarchically determines 
which CTC-derived molecular biomarkers and clinical variables fall into homogeneous 
subgroups based on a binary recursive partitioning method, classifying patients into high- 
and low-risk subgroups with respect to each outcome. The high- vs low-risk subgroups of 
CII-treated patients identified by CART analysis were further evaluated and compared for 
DFS and OS using Kaplan– Meier and Cox proportional hazard-regression models, adjusted 
for age, sex, and M category (27). All statistical analyses were performed using R version 
3.5.0 (28).
Results
DUAL mRNA/DNA MELANOMA BIOMARKER DETECTION IN ISOLATED CTCS
We evaluated for the presence of melanoma CTCs post FX1 enrichment from whole patient 
blood (see Fig. 2A in the online Data Supplement). We performed immunofluorescence 
staining on cells obtained post-FX1 isolation using MLANA antibody. MLANA expression 
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is a reported diagnostic immunohistochemistry marker for lymph node melanoma 
micrometastasis and primary melanoma (29, 30). We successfully detected MLANA-
positive cells postenrichment in 100% of patients with stage IV melanoma evaluated (n = 6; 
see Fig. 2B in the online Data Supplement). The detection capability of our dual 
mRNA/DNA CTC assay was evaluated using cells from 3 different melanoma cell lines that 
were spiked in at 100, 50, and 25 cells in 10 mL of healthy donor leukocytes across 3 
replicate experiments. Representative results (see Table 2) demonstrated a detection 
capability of mRNA/DNA biomarkers from as little as 25 melanoma cells in 10 mL of 
blood.
DETECTION OF CTC-DERIVED mRNA/DNA BIOMARKERS IN PATIENTS WITH MELANOMA
CTC mRNA/DNA biomarker status was evaluated in prospectively collected blood samples 
(n = 213) from 75 patients with known clinical status. BRAF V600E DNA mutation was 
assessed in CTC-derived DNA because it is the most frequent DNA mutation reported in 
cutaneous melanoma (31, 32). Also, BRAF V600E mutation was selected because it is a 
well-established hotspot mutation that is druggable (i.e., dabrafenib/vemurafenib/
encorafenib) compared to other frequent gene mutations found in melanoma. Detection of 
CTC-mRNA biomarkers and/or CTC-derived BRAF V600E mutation (herein referred to as 
CTC-BRAF) in respective paired BRAF-mutated (positive) metastatic tumors from these 
patients is summarized in Table 3 in the online Data Supplement; 88% of the 213 blood 
samples contained CTCs. 66 blood samples collected from 24 of 26 patients with BRAF-
V600E mutation (herein referred to as BRAF mutation) tumors were analyzed for the 
mutation hotspot. CTCs collected from 2 patients were omitted in the analysis owing to 
insufficient DNA quantities. 38% of CTC samples (n = 25 of 66) contained detectable 
BRAF mutation (mean CTC-BRAF mutation fraction, 0.05%) and were detected in 13 of 24 
patients with tumor BRAF-mutated melanoma.
Of the 63 CTCs isolated from blood samples with available LDH values, 50 CTCs contained 
corresponding low LDH (≤1.5 × URL) and 13 CTCs contained corresponding high LDH 
(>1.5× URL) in the blood. 36% of CTCs with low LDH (n = 18 of 50) and 46% of CTCs 
with high LDH (n = 6 of 13) contained detectable CTC-BRAF (see Table 4 in the online 
Data Supplement). CTC-BRAF was detected in 57% of CTCs (n = 4 of 7) negative for CTC-
mRNA biomarkers, indicating increased sensitivity of CTC biomarker detection when 
performing dual mRNA/DNA biomarker profiling. There was no significantly different 
association of CTC-BRAF detection in patients receiving BRAF/MEK inhibitor therapy 
compared to those who were not (P = 0.55, Fisher exact test). Overall, CTC-derived 
biomarkers were detected in 88% of samples evaluated. Dual mRNA/ DNA biomarker 
profiling increased the detection of CTC biomarkers in CTC-mRNA negative samples by 
57%, which increased the detection of CTCs during therapy.
CTNNB1 OVEREXPRESSION IN CTCS AS A POTENTIAL IMMUNE EVASION CII 
BIOMARKER
The CTNNB1 pathway reportedly plays a critical role in therapeutic immune evasion (33, 
34). To assess CTNNB1 expression in isolated CTCs as a potential tumor biomarker, we 
performed RNA-seq analysis on isolated CTCs from 3 patients with stage IV melanoma 
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receiving CII. RNA-seq revealed a highly overexpressed gene, CTNNB1, in melanoma 
CTCs not present in healthy blood referenced in Genotype-Tissue Expression (see Fig. 3 in 
the online Data Supplement). We verified the CTNNB1 expression in the isolated CTC-
mRNA (n = 3) through CTNNB1 qRT-PCR assay. We assessed the detection frequency of 
CTNNB1 expression in CTC-mRNA by an established qRT-PCR assay utilizing samples 
with available CTC-mRNA (n = 122). We detected CTNNB1 overexpression in 48% of 
CTC-mRNA (n = 58 of 122) and none in 10 healthy donor leukocytes post-FX1 enrichment. 
This is the first detection of CTNNB1 overexpression in CTCs isolated from patients 
receiving CII. To verify if CTC-derived CTNNB1 can serve as a surrogate tumor marker, we 
evaluated the CTNNB1 expression in CTC-matched formalin-fixed, paraffin-embedded 
tumors through RNA in situ hybridization (see Fig. 4 in the online Data Supplement) and 
identified an 87% concordance rate (n = 15; see Table 5 in the online Data Supplement) with 
discordance possibly due to low overall CTC enrichment from blood. Lastly, we identified 
that CTNNB1 expression was significantly lacking in CTCs from patients with complete 
response (n = 18) compared to PD/SD (n = 74) while on CII (P = 0.02).
PREDICTORS OF CLINICAL OUTCOMES IN CII-TREATED PATIENTS
CTC-derived molecular biomarkers may be predictive of clinical outcomes during treatment. 
We focused on patients with stage IV melanoma (n = 52) in our CART analysis, which 
included CTC biomarkers and clinical variables with respect to DFS and OS. Patient 
treatment regimens are summarized in Table 1 in the online Data Supplement. LDH, tumor 
BRAF mutation, and CTC-mRNA were identified as potentially predictive of DFS (Fig. 1A) 
and OS (Fig. 1B) based on the optimal split by CART. Specifically, LDH partitioned patients 
into highvs low-risk subgroups. CTC-mRNA biomarkers further partitioned subgroups 
followed by tumor BRAF mutation status. Interestingly, we found that 76% of patients with 
low LDH (n = 34) contained detectable CTC-mRNA (see Fig. 5A in the online Data 
Supplement), indicating presence of melanoma that may otherwise be missed by using LDH 
only. Not surprisingly, 82% of patients with high LDH (n = 11) had detectable CTC-mRNA 
(see Fig. 5B in the online Data Supplement). Subsequently, these variables (LDH, tumor 
BRAF mutation, and CTC-mRNA) were designated as a “disease outcome panel,” in which 
“high-risk” and “low-risk” melanoma patient subgroups were defined (Fig. 1). The high-risk 
subgroup contained patients with “high LDH” or “low LDH with CTC-mRNA (≥2 mRNA 
biomarker positive) and tumor BRAF WT.” The low-risk subgroup contained patients with 
“low LDH and low CTC-mRNA (<2 mRNA biomarker positive)” or “low LDH, CTC-
mRNA (≥2 mRNA biomarker positive), and tumor BRAF mutation positive.” The high-risk 
subgroup had significantly worse DFS (P = 0.03; Fig. 2A) and OS (P = 0.02; Fig. 2B). This 
significant association of the panel for DFS [hazard ratio (HR) = 2.65; 95% CI, 1.10–6.39; P 
= 0.03] and OS (HR = 4.31; 95% CI, 1.20–15.41; P = 0.02) was also identified in a 
multivariable analysis controlled for age, sex, and M category (Table 2).
CTC PROFILING IN CII-TREATED MELANOMA PATIENTS
To determine if serial CTC biomarker status is indicative of subclinical disease in blood, we 
highlight 6 out of 50 patients who experienced PD during CII (Fig. 3). Patients #1 and #2 
experienced PD while receiving treatment (Fig. 3A and B). Patient #3 with a BRAF-mutated 
tumor had a detectable CTC-BRAF mutation load reflecting PD while receiving nivolumab/
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dabrafenib/trametinib (Fig. 3C). Interestingly, the dynamic levels of CTC-BRAF were 
captured post-dabrafenib/trametinib treatment. Patient #4 experienced PD (intracranial 
progression) during the start of serial bleed monitoring (Fig. 3D) and again at week 122 of 
treatment. Patient #5 with multiple metastases (lung, liver, and spleen) experienced disease 
progression to their brain after 8 weeks (Fig. 3E). Patient #6, who was disease-free following 
complete right groin lymph node dissection, had recurrence. Overall, CTCs were 
consistently detected during monitoring of all 6 patients despite fluctuating Response 
Evaluation Criteria In Solid Tumors 1.1–defined disease burden. Therefore, serial CTC 
biomarker status can indicate presence of subclinical disease during combinatorial therapies 
in addition to computerized tomography/magnetic resonance imaging, potentially providing 
biomarker-associated real-time data to guide CII treatment follow-up.
Discussion
Management of melanoma patients undergoing CII or combinatorial therapies can be 
challenging without real-time biomarker(s) predictive of treatment response. Treatment 
efficacy on the basis of clinical symptoms or computerized tomography/magnetic resonance 
imaging can be ambiguous or delayed because tumors can enlarge (pseudo-progression) 
before responding/regressing. Minimally invasive monitoring can enable real-time 
assessment of response to treatment. Utilizing a next-generation microfluidics–based CTC 
enrichment approach, we developed a CTC microfluidic molecular workflow for assessing 
CTC biomarker status in melanoma patients during treatment. We showed robust CTC 
profiling and demonstrated concurrent mRNA/ DNA biomarker detection in patients with 
melanoma with high detection capability for CTCs during immunotherapy treatment. CTC 
profiling of dual mRNA/ DNA biomarkers detected subclinical disease in a real-time manner 
despite lack of disease-related symptoms. This study verified our melanoma biomarkers 
previously used in a direct-blood CTC assay (6, 7) and enabled molecular CTC profiling 
during CII treatment that identified new biomarkers and clinical applications for active 
monitoring of disease status/prognosis.
We focused on monitoring during CII to assess patient clinical outcomes during treatment. 
CART analysis identified a promising disease outcome blood molecular biomarker panel 
consisting of LDH, CTC-mRNA, and tumor BRAF for DFS/OS. LDH as a predictive 
variable during CII for clinical outcome is in agreement with previous reports in metastatic 
melanoma (23, 24). Novel CTC biomarkers enhance the application of real-time patient 
minimally invasive monitoring. Serial monitoring detected subclinical disease in patients 
who experienced PD. By extension, CTC monitoring may detect residual disease and assist 
in assessing tumor resistance/ progression (35).
CTNNB1 overexpression was identified as a potential CTC biomarker indicative of immune 
evasion, which supports studies in human melanoma immune invasiveness (33, 34). This 
suggests the potential of CTC escape during immune surveillance. In addition, changes in 
CTC-MLANA expression were associated with PD because it was frequently detected in 
preoperative, non-CII-treated patients with melanoma yet was only detected during follow-
up in 2 patients who recurred or experienced PD during CII (data not shown). MLANA is an 
antigenic target for active-specific immunotherapy (36), suggesting that CTC-MLANA 
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positivity could be killed during effective CII activation of antitumor immunity, whereas, in 
patients with poor antitumor immunity CTC-MLANA, positive cells escape successfully. In 
summary, CTC biomarker profiling during CII allows for better understanding of tumor 
blood metastasis dynamics beyond CTC enumeration and single biomarker assessment and 
for patient treatment stratification.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. CART analysis for disease free survival and OS in patients with stage IV melanoma (n = 
52).
(A), disease free survival and (B), OS analysis using 5 variables of which LDH, tumor-
derived BRAF mutation, and CTC-mRNA were identified as potentially predictive of DFS 
and OS. A complexity parameter of 0.001 was used. The numerator indicates number of 
disease/death (A), or death (B), and the denominator indicates total number of patients in the 
corresponding subcategory. The estimated relative event rate compared to the root node is 
indicated.
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Fig. 2. Kaplan–Meier analysis of CART-identified subgroups with DFS and OS in patients with 
stage IV melanoma receiving CII.
(A), DFS and (B), OS based on CART-identified subgroups in patients with stage IV 
melanoma (n = 52).High-risk subgroup, patients with high LDH or low LDH with CTC-
mRNA (≥2 mRNA biomarkers+) and tumor WT; low-risk subgroup, patients with low LDH 
and low CTC-mRNA (<2 mRNA biomarkers+) or low LDH and increased CTC-mRNA and 
tumor BRAF mutation positive.
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Fig. 3. CTC biomarker status in melanoma patients during combinatorial therapy with disease 
progression or recurrence.
(A), patient 1 with left calf in-transit melanoma. Patient experienced PD with metastasis to 
upper left groin on pembrolizumab despite partial response at left calf lesions. (B), patient 2 
with multiple pelvic lymph nodes and brain metastasis. Brain lesions displayed partial 
response, but pelvic lymph node disease progressed on bevacizumab treatment. (C), patient 
3 with metastases to right groin lymph nodes and gluteal region. Melanoma progressed to 
new multifocal region in left buttock area while on nivolumab and dabrafenib/trametinib. 
BRAF V600E mutation in CTCs were detected upon PD despite receiving dabrafenib/
trametinib. (D), patient 4 with metastatic melanoma in chest/back/ buttock. While on 
nivolumab/dabrafenib/trametinib treatment, PD occurred (i.e. intracranial progression). (E), 
patient 5 with multiple metastases (lung, liver, and spleen). Patient experienced progression 
to the brain and in the liver after 8 weeks despite partial response to nivolumamb and 
dabrafenib/trametinib by clinical standards. (F), patient 6 following complete right groin 
lymph node dissection. Patient recurred with multiple dermal metastases after a 10 month 
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disease–free period. Pink panels denote PD according to Response Evaluation Criteria in 
Solid Tumors 1.1 criteria. Abbreviations: Wks, weeks; *Ipi, ipilimumab; NED, no evidence 
of disease; red dashed line, LDH activities; blood-CTCs, detectable mRNA biomarkers (≥2 
biomarkers) in isolated CTCs; BRAF mutation, detectable BRAF mutation in isolated CTCs.
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Table 1.
Characteristics of AJCC patients with stage III/IV metastatic melanoma.
Characteristics Number (%)
Sex
 Male  54 (72)
 Female  21 (28)
Age, y
a
 Median (Q1, Q3) 65.8 (55.0, 72.4)
AJCC stage
 Stage III A/B/C 5/10/7
 Stage IV M1A/B/C/D 5/10/19/19
Tumor BRAF V600E
 WT  40 (53.3)
 Positive  26 (34.7)
 NA   9 (12)
LDH (U/L)
 Median (Q1, Q3) 199.0 (168.00.0, 267.0)
 Low (≤1.5× ULN)  53 (70.7)
 High (>1.5× ULN)  12 (16.0)
NA  10 (13.3)
CTC-mRNA, n (%)
 Low (<2 CTC mRNA)  16 (21.3)
 High (≥2 CTC mRNA)  59 (78.7)
CTC-BRAF
 Negative  21 (28)
 Positive  13 (17.3)
NA  41 (54.7)
CTC-CTNNB1
 Negative  16 (21.3)
 Positive  10 (13.3)
 Missing  49 (5.3)
a
Age at the time of the 1st specimen collection.
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